Your exploration stays private. Selecting a pathway does not send health information to Elyvate Wellness. This experience does not diagnose a condition or create a treatment plan.
01 / Condition selector
Which condition would you like to explore?
Select any pathway. Conditions often overlap, but exploring a card does not indicate that you have the condition.
Select a condition to begin
Your choice stays within this page and is not sent to Elyvate Wellness.
07 / From “sick care” to whole-person healthcare
What changes when the brain becomes part of the plan?
Conventional medical and psychological care can be essential for diagnosis, acute care, medication management, and evidence-based treatment. The gap often appears when a short, symptom-focused visit cannot examine why carrying out the plan feels so difficult.
COMMON SHORT-VISIT PATHWAY
Symptom-focused “sick care”
Symptoms are identified.What are you experiencing?
A diagnosis may be assigned.Medical criteria or the DSM help name the pattern.
Treatment is prescribed.Medication, advice, education, or behavioral strategies may be offered.
The person carries the plan home.The visit may not have time to evaluate cognitive overload, prospective memory, decision fatigue, sleep, or biological barriers to follow-through.
This pathway is not inherently inadequate. The limitation is that brief or siloed care may leave the implementation burden with the patient.
B3 MODEL OF CARE™
Capacity-aware healthcare
Understand the biology.What physiological factors may be creating strain?
Examine brain capacity.How are sleep, attention, memory, emotion, cognitive load, and decision-making functioning?
Make the plan doable.Reduce overload and add environmental, prospective-memory, and regulation supports.
Sequence biological and behavioral care.Implement medically appropriate nutrition, movement, recovery, psychological, and behavior-change strategies at a pace the person can carry.
The B3 framework complements appropriate medical and mental-health care. It does not replace diagnosis, medication, psychotherapy, or specialist treatment.
The brain is the processor carrying out the plan.
B3 asks whether that processor has enough cognitive and physiological capacity before expecting increasingly complex behavior. The goal is to make healthy action more achievable—not to promise perfect brain function or guaranteed results.
Why the distinction matters
A diagnosis can accurately name a condition and a treatment can be evidence-based, yet the plan can still fail at the point of implementation. Diabetes standards explicitly recognize that cognition, functional capacity, regimen complexity, hypoglycemia risk, and available support should shape care. The international PMOS guideline similarly integrates metabolic, reproductive, sleep, eating, and psychological domains. B3 applies that same research-informed logic across the full loop: identify the biology, assess what the brain is being asked to manage, then design medical, nutritional, psychological, and behavioral support that the person can realistically carry out.
Research context: American Diabetes Association (2026); Teede et al. (2023); condition-specific sources in the library below.
08 / Master reference library
Research behind the current pathways
Search or filter the complete source set currently cited in this educational preview. Each link opens the DOI record in a new tab.
Showing 27 of 27 references
Insulin ResistanceReview2026
Erukulla, R., Reid, G., Yotter, C., Dounavi, M.-E., Low, A., O’Brien, J. T., Ritchie, C., Lawlor, B., Naci, L., Malhotra, P., & Koychev, I. (2026). Insulin resistance and brain health in midlife: A potential dementia prevention target. eBioMedicine, 131, 106448. DOI / stable record
PrediabetesCohort & Mendelian randomization2026
Han, S., Naderi, E., Wang, K., Ma, Y., Biessels, G. J., & Ahmadizar, F. (2026). Prediabetes as a critical stage for risk of dementia and stroke: Evidence from the UK Biobank and Mendelian randomization. European Journal of Preventive Cardiology. DOI / stable record
Type 2 DiabetesSystematic review2026
You, Y., Wang, J., Yan, Y., Zhang, S., Zhu, W., & Xiong, Y. (2026). Diffusion magnetic resonance imaging models for detecting brain microstructural abnormalities in type 2 diabetes: A systematic review. Bioengineering, 13(7), 730. DOI / stable record
PMOS (formerly PCOS)Clinical guideline2023
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. DOI / stable record
PMOS (formerly PCOS)Global consensus2026
Teede, H. J., Khomami, M. B., Morman, R., et al. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339. DOI / stable record
Hypothyroidism & Hashimoto’sMeta-analysis2016
Rieben, C., Segna, D., da Costa, B. R., Collet, T.-H., Chaker, L., Aubert, C. E., Baumgartner, C., Almeida, O. P., Hogervorst, E., Trompet, S., Masaki, K., Mooijaart, S. P., Gussekloo, J., Peeters, R. P., Bauer, D. C., Aujesky, D., & Rodondi, N. (2016). Subclinical thyroid dysfunction and the risk of cognitive decline: A meta-analysis of prospective cohort studies. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4945–4954. DOI / stable record
Perimenopause & MenopauseClinical review2024
Maki, P. M., & Jaff, N. G. (2024). Menopause and brain fog: How to counsel and treat midlife women. Menopause, 31(7), 647–649. DOI / stable record
Insulin ResistanceState-of-science review2024
Rhea, E. M., Leclerc, M., Yassine, H. N., Capuano, A. W., Tong, H., Petyuk, V. A., Macauley, S. L., Fioramonti, X., Carmichael, O., Calon, F., & Arvanitakis, Z. (2024). State of the science on brain insulin resistance and cognitive decline due to Alzheimer’s disease. Aging and Disease, 15(4), 1688–1725. DOI / stable record
Wagner, L., Veit, R., Kübler, C., Fritsche, A., Häring, H.-U., Birkenfeld, A. L., Heni, M., Preissl, H., & Kullmann, S. (2023). Brain insulin responsiveness is linked to age and peripheral insulin sensitivity. Diabetes, Obesity and Metabolism, 25(8), 2171–2180. DOI / stable record
Type 2 DiabetesSystematic review & meta-analysis2019
Xue, M., Xu, W., Ou, Y.-N., Cao, X.-P., Tan, M.-S., Tan, L., & Yu, J.-T. (2019). Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. Ageing Research Reviews, 55, 100944. DOI / stable record
PMOS (formerly PCOS)Longitudinal cohort2024
Huddleston, H. G., Jaswa, E. G., Casaletto, K. B., Neuhaus, J., Kim, K. H., Wellons, M. F., Launer, L. J., & Yaffe, K. (2024). Associations of polycystic ovary syndrome with indicators of brain health at midlife in the CARDIA cohort. Neurology, 102(4), e208104. DOI / stable record
Pankowski, D., & Wytrychiewicz-Pankowska, K. (2025). Prevalence, hormonal correlates, severity, and neural basis of neurocognitive impairment in patients with hypothyroidism: Systematic review and meta-analyses. Alzheimer’s & Dementia, 21(11), e70924. DOI / stable record
Andy, C., Nerattini, M., Jett, S., Carlton, C., Zarate, C., Boneu, C., Fauci, J., Ajila, V., Battista, T., Pahlajani, S., Christos, P. J., Fink, M. E., Williams, S., Brinton, R. D., & Mosconi, L. (2024). Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Frontiers in Endocrinology, 15, 1350318. DOI / stable record
Perimenopause & MenopausePosition statement2023
The North American Menopause Society. (2023). The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause, 30(6), 573–590. DOI / stable record
Wang, J., Bi, C., Xi, H., & Wei, F. (2024). Effects of administering berberine alone or in combination on type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1455534. DOI / stable record
Gholami, Z., Clark, C. C. T., & Paknahad, Z. (2024). The effect of psyllium on fasting blood sugar, HbA1c, HOMA-IR, and insulin control: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders, 24(1), 82. DOI / stable record
PrediabetesSystematic review & meta-analysis2024
Gholami, Z., Clark, C. C. T., & Paknahad, Z. (2024). The effect of psyllium on fasting blood sugar, HbA1c, HOMA-IR, and insulin control: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders, 24(1), 82. DOI / stable record
PrediabetesSystematic review & meta-analysis2016
Simental-Mendía, L. E., Sahebkar, A., Rodríguez-Morán, M., & Guerrero-Romero, F. (2016). A systematic review and meta-analysis of randomized controlled trials on the effects of magnesium supplementation on insulin sensitivity and glucose control. Pharmacological Research, 111, 272–282. DOI / stable record
Type 2 DiabetesSystematic review & meta-analysis2024
Wang, J., Bi, C., Xi, H., & Wei, F. (2024). Effects of administering berberine alone or in combination on type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1455534. DOI / stable record
Type 2 DiabetesSafety review2026
Dumitru, C. N., Marcu, T., Dumitru, A. O., et al. (2026). Berberine-drug interactions: Mechanisms, clinical relevance and risk stratification—A narrative review. Pharmaceuticals, 19(8), 1313. DOI / stable record
Type 2 DiabetesSystematic review & meta-analysis2024
Gholami, Z., Clark, C. C. T., & Paknahad, Z. (2024). The effect of psyllium on fasting blood sugar, HbA1c, HOMA-IR, and insulin control: A GRADE-assessed systematic review and meta-analysis of randomized controlled trials. BMC Endocrine Disorders, 24(1), 82. DOI / stable record
Fitz, V., Graca, S., Mahalingaiah, S., et al. (2024). Inositol for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 update of the international evidence-based PCOS guidelines. The Journal of Clinical Endocrinology & Metabolism, 109(6), 1630–1655. DOI / stable record
Guo, Q., Du, R., Guo, C., & Ma, S. (2026). Association between serum vitamin D levels and insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis. Journal of Obstetrics and Gynaecology Research, 52(7), e70393. DOI / stable record
Peng, B., Wang, W., Gu, Q., Wang, P., Teng, W., & Shan, Z. (2024). Effects of different supplements on Hashimoto’s thyroiditis: A systematic review and network meta-analysis. Frontiers in Endocrinology, 15, 1445878. DOI / stable record
Larsen, C., Winther, K. H., Cramon, P. K., et al. (2024). Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. European Thyroid Journal, 13(1), e230175. DOI / stable record
Perimenopause & MenopauseRandomized pilot trial2012
Jenks, B. H., Iwashita, S., Nakagawa, Y., et al. (2012). A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency. Journal of Women’s Health, 21(6), 674–682. DOI / stable record
Gençtürk, N., Bilgiç, F. Ş., & Kaban, H. U. (2024). The effect of soy isoflavones given to women in the climacteric period on menopausal symptoms and quality of life: Systematic review and meta-analysis of randomized controlled trials. Explore, 20(6), 103012. DOI / stable record
Educational prototype—not medical advice
This experience does not diagnose metabolic or hormonal conditions, assess your symptoms, or provide personalized treatment. Seek evaluation from an appropriate licensed healthcare professional for new, severe, urgent, or unexplained symptoms. If you may be experiencing a medical emergency, contact emergency services.
Choose your next step
Continue in the way that feels right for you
OPTION 01
Discover What May Be Getting in the Way
The free Health Roadblock Assessment can help you identify biological, brain-based, and behavioral barriers that may be making healthy change more difficult. Your results will provide an initial look at where you may need greater support.
Take the Free Assessment External destination: Elyvate Wellness Health Roadblock AssessmentOPTION 02
Not Sure What Your Next Step Should Be?
If you would rather discuss your concerns and possible next steps directly, schedule a consultation with Heidi. Talk through what you have been experiencing and determine which Elyvate Wellness pathway may be appropriate.
Scientific content is developed from peer-reviewed research, prioritizing systematic reviews, meta-analyses, clinical guidelines, longitudinal cohorts, randomized trials, and high-quality human neuroimaging. Evidence labels describe the strength of each relationship—not the seriousness of a condition. Association is not presented as causation. Animal, cellular, and indirect mechanistic findings are labeled separately. Consensus will be used as an additional cross-check when access becomes available.
Privacy statement
This educational pathway does not request or collect names, contact information, diagnoses, symptoms, laboratory results, medication lists, or other health information. Condition and mechanism selections operate only within the page and are not transmitted to Elyvate Wellness. External services have their own privacy practices.
Accessibility statement
This experience is designed for keyboard navigation, screen readers, reduced-motion preferences, mobile displays, visible focus, and text alternatives for the brain explorer. If you experience an accessibility barrier, contact Elyvate Wellness through its official website so an alternative format can be provided.
Terms and educational scope
Content is for general education and wellness support. It is not medical or mental-health diagnosis, treatment, emergency guidance, or a clinician–patient relationship. Do not delay professional care because of information presented here. Research changes over time, and individual outcomes vary.